Chinook therapeutics revenue
WebApr 13, 2024 · Chinook Therapeutics, Inc. SEATTLE, April 13, 2024 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical … WebChinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines ... EPS and …
Chinook therapeutics revenue
Did you know?
WebFeb 27, 2024 · chinook therapeutics - cash, cash equivalents and marketable securities totaled $385.3 million as of dec 31, 2024, versus $355.1 million as of dec 31, 2024 QTRLY REVENUE WAS $0.5 MILLION Q4 EARNINGS PER SHARE VIEW $-0.79, REVENUE VIEW $100000.00 — REFINITIV IBES DATA WebNov 16, 2024 · Chinook Therapeutics (NASDAQ:KDNY) Third Quarter 2024 ResultsKey Financial Results. Revenue: US$2.50m (up by US$2.50m from 3Q 2024). Net loss: …
WebMar 25, 2024 · This is a summary of current ratings and price targets for Bio-Path and Chinook Therapeutics, as provided by MarketBeat. Bio-Path presently has a consensus price target of $9.00, indicating a ... WebApr 10, 2024 · An auction of Pear’s assets is expected to happen in early May. Pear Therapeutics’ search for a buyer has yet to lead to a consummated deal, and the …
Web2 days ago · A recent report from the Kaiser Family Foundation estimated that nonprofit hospitals were exempt from paying nearly $28 billion in taxes in 2024, up 41% from their about $20 billion in tax breaks ... WebFeb 24, 2024 · Chinook Therapeutics is a biotechnology company developing precision medicines for kidney diseases. The company applies its proprietary discovery platform, …
WebApr 13, 2024 · Chinook Therapeutics, Inc. SEATTLE, April 13, 2024 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and ...
WebFeb 27, 2024 · Chinook Therapeutics (KDNY) came out with a quarterly loss of $0.90 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to earnings of $0.14 per share a year ago. These ... porphyry copper assessment of mexicoWebNov 8, 2024 · Chinook (KDNY) delivered earnings and revenue surprises of 17.07% and -98.40%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? porphyry cave of the nymphsWebApr 14, 2024 · Chinook Therapeutics had a negative return on equity of 40.61% and a negative net margin of 3,065.68%. The firm’s revenue was down 90.0% on a year-over-year basis. As a group, analysts predict that Chinook Therapeutics, Inc. will post -3.19 earnings per share for the current year. Insider Activity porphyry copper alteration zonesWebFeb 25, 2024 · The revenue for CHK-336 is expected to reach an annual total of $24 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along … porphyry biography of plotinusWebFeb 27, 2024 · Chinook Therapeutics (KDNY) came out with a quarterly loss of $0.90 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compare... porphyry basin coloradoWebApr 14, 2024 · The firm had revenue of $5.10 million during the quarter, compared to analyst estimates of $0.10 million. Chinook Therapeutics’s revenue was down 90.0% on a year-over-year basis. As a group, equities analysts forecast that Chinook Therapeutics will post -3.19 earnings per share for the current fiscal year. Insider Activity at Chinook … porphyry copper deposits pptWebSep 30, 2024 · SEATTLE, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the third quarter ended September 30, … porphyry art